Gracell Biotechnologies Inc. (GRCL) — Financial Flexibility Index
Gracell Biotechnologies Inc. (GRCL) has a Financial Flexibility Index of -0.26x as of March 2021. Free cash flow of $-49.84 Million (operating CF $-63.95 Million minus capex $14.11 Million) represents 0% of total liabilities ($193.62 Million). Check Gracell Biotechnologies Inc. tangible book value ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Gracell Biotechnologies Inc. Financial Flexibility Index (2018–2022)
Historical Financial Flexibility Index trend for Gracell Biotechnologies Inc. across 5 annual periods. For the full cash flow conversion analysis, see Gracell Biotechnologies Inc. (GRCL) cash conversion ratio.
Annual Financial Flexibility Index for Gracell Biotechnologies Inc. (2018–2022)
Year-by-year free cash flow to debt coverage for Gracell Biotechnologies Inc.. Explore Gracell Biotechnologies Inc. cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2022 | -10.61x | $-2.98 Billion | $-3.31 Billion | $280.51 Million | ▼ -896.4% |
| 2021 | -1.06x | $-247.81 Million | $-304.55 Million | $232.77 Million | ▼ -30.3% |
| 2020 | -0.82x | $-118.75 Million | $-198.15 Million | $145.29 Million | ▼ -62.4% |
| 2019 | -0.50x | $-78.96 Million | $-135.39 Million | $156.86 Million | ▼ -45.7% |
| 2018 | -0.35x | $-50.50 Million | $-61.86 Million | $146.13 Million | — |